Table 3.
Univariate and multivariate analysis of clinicopathologic factors in NSCLC patients with respect to PFS.
| Cases n (%) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| Survival time (months) | P-value | HR (95%CI) | P-value | ||
| AGE (YEARS) | |||||
| <60 | 50 (39) | 45.56 (5.45) | 0.962 | ||
| ≥60 | 79 (61) | 43.94 (4.04) | |||
| GENDER | |||||
| Male | 74 (57) | 44.64 (4.37) | 0.801 | ||
| Female | 55 (43) | 41.02 (3.69) | |||
| SMOKING STATUS | |||||
| Never smoke | 61 (47) | 43.78 (3.46) | 0.233 | ||
| Smoke | 68 (53) | 42.89 (4.49) | |||
| HISTOLOGICAL TYPE | |||||
| SCC | 41 (32) | 44.47 (5.52) | 0.711 | ||
| ADC | 88 (68) | 45.65 (4.11) | |||
| TNM STAGE | |||||
| I-II | 61 (47) | 54.06 (4.55) | 0.002 | 1.122 (0.563-2.237) | 0.744 |
| III-IV | 68 (53) | 31.47 (3.14) | |||
| TUMOR SIZE | |||||
| ≤3 cm | 79 (61) | 54.45 (4.08) | <0.0001 | 2.216 (1.289-3.808) | 0.004 |
| >3 cm | 50 (39) | 25.15 (3.26) | |||
| LYMPHATIC INVASION | |||||
| Negative | 47 (36) | 56.05 (5.30) | 0.002 | 1.665 (0.814-3.404) | 0.163 |
| Positive | 82 (64) | 38.26 (3.86) | |||
| SUVmax | |||||
| <9.5 | 66 (51) | 56.22 (4.39) | <0.0001 | 1.682 (0.945-2.995) | 0.077 |
| ≥9.5 | 63 (49) | 28.62 (3.16) | |||
| NOP EXPRESSION | |||||
| Low | 72 (56) | 56.31 (4.39) | <0.0001 | 2.291 (1.394-3.767) | 0.001 |
| High | 57 (44) | 28.81 (3.56) | |||
| OPIOID REQUIREMENT | |||||
| OME <5 mg/day | 96(74) | 46.55 (4.88) | 0.833 | ||
| OME≥5 mg/day | 33(26) | 44.32 (4.16) | |||
SCC, Squamous cell carcinoma; ADC, Adenocarcinoma; SUVmax, the maximum standardized uptake value; NOP, nociceptin receptor; OME, oral morphine equivalents. Progression free survival (PFS) time were presented as mean (SEM) and were determined by the Kaplan-Meier method with log-rank test. Multivariable analysis of the independent factors was performed by the Cox proportional hazard model.